Business
Health Hope Pharma Enters into Exclusive Licensing Agreement with Gilead Sciences
Health Hope Pharma Limited ("HHP") today announced that it has entered into a global licensing and collaboration agreement with Gilead Sciences, Inc. ("Gilead") for encequidar, a first-in-class P-glycoprotein ("P-gp") inhibitor in the field of virology.
About this update from Gilead Sciences, Inc.
[{"type":"list","items":[{"val":[{"type":"text","content":"HHP and Hanmi will grant Gilead exclusive license to encequidar, and provide access to drug supply","length":98,"tagName":"p"}]}],"tagName":"ul","bulletedList":true,"length":98,"olType":false},{"type":"text","content":"HONG KONG, Sept. 29, 2025 /PRNewswire/ -- Health Hope Pharma Limited ("HHP") today announced that it has entered into a global licensing and collaboration agreement with Gilead Sciences, Inc. ("Gilead") for encequidar, a first-in-class P-glycoprotein ("P-gp") inhibitor in the field of virology.","length":325,"tagName":"p"},{"type":"image","alt":"(PRNewsfoto/Health Hope Pharma)","displaySize":"","headline":null,"caption":"(PRNewsfoto/Health Hope Pharma)","className":"","disableSlideshowImg":false,"size":{"original":{"width":400,"height":112,"url":"https://media.zenfs.com/en/prnewswire.com/5c8d8b1435ac91baa74fa67e5092b5c6"},"resized":{"url":"https://s.yimg.com/ny/api/res/1.2/ByAE3EmX8yB5VuPga8LEXw--/YXBwaWQ9aGlnaGxhbmRlcjt3PTcwNTtoPTE5NztjZj13ZWJw/https://media.zenfs.com/en/prnewswire.com/5c8d8b1435ac91baa74fa67e5092b5c6","width":400,"height":112}},"href":"https://mma.prnewswire.com/media/2784309/WhatsApp_Image_2025_09_29_at_6_04_26_PM_Logo.html","hrefExternal":true,"rel":"nofollow"},{"type":"text","content":"HHP is currently exploring the potential of using encequidar to develop oral drug formulations across multiple fields. The most advanced program of HHP is oral paclitaxel combined with encequidar in the field of oncology, targeting to replace intravenous paclitaxel in chemotherapy for metastatic breast cancer. HHP targets to recruit the first patients for its global phase III clinical study for sites in the U.S. and Hong Kong SAR, respectively, by the fourth quarter of 2025.","length":479,"tagName":"p"},{"type":"text","content":"Under the agreement, HHP and Hanmi Pharm ("Hanmi") will grant Gilead exclusive global rights to encequidar within the field of virology. In addition, HHP and Hanmi will provide drug supply, share technical know-how, and participate as key project partners. HHP and Hanmi will each receive an upfront payment and are eligible to receive development, regulatory and sales milestones in addition to low single-digit royalties on net sales.","length":446,"tagName":"p"},{"type":"text","content":"Prof . Dennis Lam, founder of...